Clearwater International acted as financial advisor in the sale of Maribo Medico, Denmark’s market leader in sleep and respiratory care, to listed US-based ResMed (NYSE:RMD).
Founded in 1996/1997 and based in Sjaelland, Denmark, Maribo Medico is Denmark’s leading value-added distributor specialising in providing quality products, compliance and education relating to the diagnosis, treatment and management of sleep-disordered breathing and respiratory diseases.
Maribo Medico has been ResMed’s exclusive distribution partner in Denmark for more than 15 years. Together, ResMed and Maribo will help to improve the lives of the many thousands of people in Denmark who suffer from obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD).
“Through dedicated and skilful advice, Clearwater did an excellent job in supporting us in the sale of our business. We experienced high level capabilities in understanding, not just for our current business and market situation but also for the wishes we had for our company in a new owner structure. We were impressed with the deal team’s ability to keep the sale process on track in highly difficult periods and their ability to ensure maximum value combined with a satisfactory deal structure. Throughout the whole process – and especially in the key moments of the transaction – they were very close at our side. Without any hesitations, we would recommend others in our situation to engage with Clearwater.”
Henrik Rømer, CFO and part-owner of Maribo Medico
“Maribo Medico is a well-run medical device distributor, delivering a strong value-add to its customers through unique know-how and service. Over the years, Maribo Medico has underlined its market-leading position by becoming the primary meeting place for the sleep industry, when they host the annual sleep conference or one of their seminars.
The business has grown strongly over the years – supported by a strong product offering from ResMed – and I believe that as part of the ResMed organisation, Maribo Medico will be able to strengthen its position in the Danish market and continue its efforts to improve the quality of life for OSA patients in Denmark.”
Lars Thorup Gregersen, Associate Partner at Clearwater International